519 related articles for article (PubMed ID: 23329465)
1. Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
Lomonaco R; Sunny NE; Bril F; Cusi K
Drugs; 2013 Jan; 73(1):1-14. PubMed ID: 23329465
[TBL] [Abstract][Full Text] [Related]
2. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
[TBL] [Abstract][Full Text] [Related]
3. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
Stein LL; Dong MH; Loomba R
Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118
[TBL] [Abstract][Full Text] [Related]
4. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
5. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.
Chalasani NP; Sanyal AJ; Kowdley KV; Robuck PR; Hoofnagle J; Kleiner DE; Unalp A; Tonascia J;
Contemp Clin Trials; 2009 Jan; 30(1):88-96. PubMed ID: 18804555
[TBL] [Abstract][Full Text] [Related]
7. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
Budd J; Cusi K
Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment.
Smith BW; Adams LA
Nat Rev Endocrinol; 2011 May; 7(8):456-65. PubMed ID: 21556019
[TBL] [Abstract][Full Text] [Related]
9. Vitamin E and nonalcoholic fatty liver disease.
Pacana T; Sanyal AJ
Curr Opin Clin Nutr Metab Care; 2012 Nov; 15(6):641-8. PubMed ID: 23075940
[TBL] [Abstract][Full Text] [Related]
10. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
11. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
Gastaldelli A; Harrison SA; Belfort-Aguilar R; Hardies LJ; Balas B; Schenker S; Cusi K
Hepatology; 2009 Oct; 50(4):1087-93. PubMed ID: 19670459
[TBL] [Abstract][Full Text] [Related]
12. State of the art: treatment of nonalcoholic steatohepatitis.
Pearlman M; Loomba R
Curr Opin Gastroenterol; 2014 May; 30(3):223-37. PubMed ID: 24717764
[TBL] [Abstract][Full Text] [Related]
13. [Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis].
Heebøll S; Kazankov K; Poulsen MK; Vilstrup H; Grønbæk H
Ugeskr Laeger; 2012 Feb; 174(8):488-90. PubMed ID: 22348670
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease: new treatments.
Hardy T; Anstee QM; Day CP
Curr Opin Gastroenterol; 2015 May; 31(3):175-83. PubMed ID: 25774446
[TBL] [Abstract][Full Text] [Related]
15. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
Corey KE; Rinella ME
Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
[TBL] [Abstract][Full Text] [Related]
16. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials.
An J; Sohn JH
Clin Mol Hepatol; 2023 Feb; 29(Suppl):S268-S275. PubMed ID: 36537018
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.
Sanyal AJ; Mofrad PS; Contos MJ; Sargeant C; Luketic VA; Sterling RK; Stravitz RT; Shiffman ML; Clore J; Mills AS
Clin Gastroenterol Hepatol; 2004 Dec; 2(12):1107-15. PubMed ID: 15625656
[TBL] [Abstract][Full Text] [Related]
19. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
